Due to the shortcomings of cystoscopy and cytology, there has been great interest in identifying tumour biomarkers detectable in the urine that could provide a more sensitive and objective test for the early detection of bladder cancer and its recurrence. However, none of the currently available urine markers that are approved by the FDA can be recommended without limitations for clinical use. EI-BLA, our inventive 2-gene biomarker panel is more specific than any of these detection systems and thus constitutes a promising new approach for early bladder cancer detection.
The ECRG4 and ITIH5 gene promoter methylation has been identified as a novel biomarker panel for the early detection of bladder cancer. Its strong diagnostic potential has been demonstrated in a larger cohort of urine samples from bladder cancer vs. healthy controls. A further screening trial using independent (multicenter) urine samples has been initiated.
- EI-BLA, a novel biomarker panel for the early detection of bladder cancer from Urine
- Level of promoter methylation can be easily assessed with robust standard techniques
- Specificity of 100%, sensitivity of 84%
- Non-invasive approach for early bladder cancer detection
Current Patent Status
In case of interest we are pleased to inform you about the patent status.